stoxline Quote Chart Rank Option Currency Glossary
  
Fractyl Health, Inc. Common Stock (GUTS)
1.63  -0.01 (-0.61%)    02-06 11:27
Open: 1.65
High: 1.6874
Volume: 49,813
  
Pre. Close: 1.64
Low: 1.605
Market Cap: 78(M)
Technical analysis
2025-02-06 10:48:27 AM
Short term     
Mid term     
Targets 6-month :  2.3 1-year :  2.63
Resists First :  1.97 Second :  2.25
Pivot price 1.85
Supports First :  1.51 Second :  1.26
MAs MA(5) :  1.67 MA(20) :  1.85
MA(100) :  2.25 MA(250) :  4.36
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  13 D(3) :  9.6
RSI RSI(14): 38.3
52-week High :  10.68 Low :  1.51
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GUTS ] has closed above bottom band by 18.4%. Bollinger Bands are 13.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.68 - 1.7 1.7 - 1.71
Low: 1.49 - 1.51 1.51 - 1.52
Close: 1.62 - 1.64 1.64 - 1.66
Company Description

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.

Headline News

Mon, 01 Apr 2024
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewswire

Mon, 05 Feb 2024
Firm Advises Fractyl Health on Patent Matters Related to $110 Million IPO - Wilson Sonsini

Sun, 04 Feb 2024
StockWatch: Alto, Fractyl, FibroBiologics Join Parade of Public Biotechs - Genetic Engineering & Biotechnology News

Fri, 02 Feb 2024
Fractyl Health Prices 7.33M Share IPO at $15/sh By Investing.com - Investing.com UK

Fri, 02 Feb 2024
Fractyl Health goes the IPO route - Drug Delivery Business News

Fri, 02 Feb 2024
Latham & Watkins Advises Fractyl Health on Initial Public Offering - Latham & Watkins LLP

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 48 (M)
Held by Insiders 1.745e+007 (%)
Held by Institutions 4.8 (%)
Shares Short 2,210 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -8.081e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -169 %
Return on Assets (ttm) 957.1 %
Return on Equity (ttm) -55.4 %
Qtrly Rev. Growth 97000 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.6 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -59 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 2.73e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android